Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenobarbitone (low certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ Generalized onset seizures (tonic‐clonic only) Range of · adults and children with newly onset partial or generalised epilepsy
Carbamazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenobarbitone (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to achieve 12‐month remission (seizure‐free period) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to 12‐month remission ‐ stratified by epilepsy type ‐ generalised onset Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) Subgroup:… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure (any reason related to treatment)… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).
1 finding from 1 review
Time to treatment failure due to lack of efficacy All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to treatment failure due to lack of efficacy All participants… compared with phenytoin (primary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) All participants Range of compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: focal onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: focal onset… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) Subgroup: generalised onset seizures Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to first seizure (post‐randomisation) Subgroup: generalised… compared with phenytoin (secondary outcomes) (low certainty).
1 finding from 1 review
Remission · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine showed no clear difference in time to achieve 12‐month remission (seizure‐free period) All… compared with phenytoin (secondary outcomes) (moderate certainty).
1 finding from 1 review
Time on allocated treatment (retention time) · people with focal or generalized seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
50% responder rate · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects requiring withdrawal/discontinuation of study medication · drug‐naïve people with focal or generalized seizures with solitary cysticercus granuloma
Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).
1 finding from 1 review
Retention [ · people with focal or generalized seizures
Clobazam showed no clear difference in retention at 12 months compared with carbamazepine (low certainty).
1 finding from 1 review
Seizure freedom · people with focal or generalized seizures
Clobazam showed no clear difference in seizure freedom at 4 weeks compared with carbamazepine (low certainty).
2 findings from 1 review
50% responder rate · people with focal or generalized seizures
Clobazam showed no clear difference in 50% responder rate compared with carbamazepine (low certainty).
1 finding from 1 review